Abstract
Purpose: Pemetrexed is licensed for use in mesothelioma and non-small-cell lung cancer. Early clinical development indicated that it causes cytotoxicity with dose (efficacy) limiting gastrointestinal (GI) and blood toxic effects. Use of folic acid and vitamin B12 reduced these toxicities. This study was undertaken to assess the effectiveness of a risk minimization program based on administration of folic acid and vitamin B12 to reduce the therapeutic toxicity of pemetrexed and physicians' compliance with these measures.Methods: Lilly Safety Database was searched for reports of GI and blood toxicity associated with pemetrexed. The period of early development was compared with the subsequent period in which risk minimization measures were in place. Reports from the postmarketing period were assessed to determine the percentage reported with appropriate risk minimization supplemention.Results: The proportion of severe GI and blood toxicity in clinical trials was lower after the introduction of supplementatio...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
